ZEMANEK, David, Jaroslav JANUSKA, Tomáš HONEK, Karol CURILA, Milos KUBANEK, Stepanka SINDELAROVA, Lucie ZAHALKOVA, Petr KLOFAC, Eliska LASTUVKOVA, Eva LICHNEROVA, Renata AIGLOVA, Jan LHOTSKY, Jiri VONDRAK, Gabriela DOSTALOVA, Milos TABORSKY, David KASPER a Ales LINHART. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic. ESC Heart Failure. San Francisco: Wiley Periodicals, 2022, roč. 9, č. 6, s. 4160-4166. ISSN 2055-5822. Dostupné z: https://dx.doi.org/10.1002/ehf2.14135.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic
Autoři ZEMANEK, David (203 Česká republika), Jaroslav JANUSKA (203 Česká republika), Tomáš HONEK (203 Česká republika, domácí), Karol CURILA (203 Česká republika), Milos KUBANEK (203 Česká republika), Stepanka SINDELAROVA (203 Česká republika), Lucie ZAHALKOVA (203 Česká republika), Petr KLOFAC (203 Česká republika), Eliska LASTUVKOVA (203 Česká republika), Eva LICHNEROVA (203 Česká republika), Renata AIGLOVA (203 Česká republika), Jan LHOTSKY (203 Česká republika), Jiri VONDRAK (203 Česká republika), Gabriela DOSTALOVA (203 Česká republika), Milos TABORSKY (203 Česká republika), David KASPER (203 Česká republika) a Ales LINHART (203 Česká republika, garant).
Vydání ESC Heart Failure, San Francisco, Wiley Periodicals, 2022, 2055-5822.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.800
Kód RIV RIV/00216224:14110/22:00128280
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1002/ehf2.14135
UT WoS 000852286600001
Klíčová slova anglicky Fabry disease; Hypertrophic cardiomyopathy; Screening; Alpha-galactosidase; Lyso-Gb(3); Genetic testing
Štítky 14110115, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 25. 1. 2023 14:35.
Anotace
Aims Fabry disease (FD) is a rare X-linked genetic disorder caused by a-galactosidase A (AGALA) deficiency. Whereas 'classic' variant has multisystemic manifestation, the more recently described 'later-onset' variant is characterized by predominant cardiac involvement that often mimics hypertrophic cardiomyopathy (HCM). Methods and results Consecutive unrelated patients with HCM were screened for FD in 16 (out of 17) cardiac centres in the Czech Republic covering specialized cardiology care from June 2017 to December 2018. AGALA activity and globotriaosylsphingosine (lyso-Gb(3)) levels were measured in all subjects using the dry blood spot method. FD was suspected in male patients with AGALA activity <1.2 mu mol/h/L and in females with either low AGALA activity or lyso-Gb(3) > 3.5 ng/mL. Positive screening results were confirmed by genetic testing. We evaluated 589 patients (390 males, 66%) with HCM (mean maximal myocardial thickness 19.1 +/- 4.3 mm). The average age was 58.4 +/- 14.7 years. In total, 17 patients (11 males, 6 females) had a positive screening result, and subsequently, six of them (four males and two females) had a genetically confirmed pathogenic GLA mutation (total prevalence of 1.02%). Five of these patients were carrying the p.N215S mutation known to cause a typical later-onset cardiac FD. Conclusions We confirmed the prevalence of FD repeatedly reported in previous screening programmes (approximately 1% irrespective of gender) in a non-selected HCM population in Central Europe. Our findings advocate a routine screening for FD in all adult patients with HCM phenotype including both genders. The dry blood spot method used led to identification of clearly pathogenic variants.
VytisknoutZobrazeno: 21. 5. 2024 20:17